Mosaic Intelligence Labs

Cover Block

Publicly reported

Field	Value
Name	Mosaic Intelligence Labs
Tagline	Developing sensing-enabled instruments, spatial intelligence, and robotic systems for minimally invasive surgery.
Headquarters	San Francisco, US [Business Wire, November 2026]
Stage	Seed [Business Wire, November 2026]
Business model	Hardware + Software
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth profile	Venture Scale
Founding team	Co-Founders (2): Dr. Ileana Pirozzi and Dr. Alison “Ali” Kight Mackanic [Business Wire, November 2026] [The Next Web, November 2026]
Funding label	Seed
Total disclosed	~$47,000,000 [Business Wire, November 2026]

Links

Publicly reported

• LinkedIn: https://www.linkedin.com/in/ileanapirozzi/
• Ashby: https://jobs.ashbyhq.com/mosaicintelligence

Summary and Signal

PUBLIC Mosaic Intelligence Labs is building sensing-enabled instruments, spatial intelligence software, and robotic systems for minimally invasive surgery, and it merits investor attention now because it emerged from stealth in November 2026 with a notably large $47 million seed financing for a still-early surgical robotics platform [Business Wire, November 2026] [The Next Web, November 2026]. The company’s public story is straightforward: co-founders Dr. Ileana Pirozzi and Dr. Alison "Ali" Kight Mackanic met during their doctoral studies at Stanford, and Mosaic says that operating room observation shaped its view that procedural outcomes still depend heavily on operator judgment and interpretation [Business Wire, November 2026] [The Next Web, November 2026].

The initial wedge appears to be endovascular procedures, where Mosaic is developing AI-guided catheters, sensing-enabled instruments, 3D vessel reconstruction, and robotic controls intended to help physicians understand anatomy and instrument position with less reliance on X-ray guidance and operator "feel" [The Next Web, November 2026] [Runtime Wire, November 2026] [Business Wire, November 2026]. That framing matters because endovascular intervention already presents a real technical bottleneck around real-time catheter and guidewire tracking for robotic control, while conventional sensor-embedded approaches can add fabrication complexity and miniaturization constraints [Frontiers, 2026] [arXiv, 2025].

On team quality, the public record supports only a narrow but relevant read: Pirozzi is identified as CEO and Mackanic as CTO, and both are described in coverage as Stanford-trained scientists rather than repeat medtech operators with a disclosed commercialization history [Business Wire, November 2026] [The Next Web, November 2026]. That does not weaken the technical ambition, but it does mean investors are still underwriting a platform largely on founder-market fit and early technical narrative rather than on demonstrated regulatory, clinical, or go-to-market execution.

Capital formation is the clearest external signal so far. Mosaic disclosed roughly $47 million in seed funding, with 8VC, Fundomo, Lingotto Innovation, and Obvious Ventures named as backers, and the company is hiring across hardware, software, and clinically deployed engineering, which is consistent with a hardware-plus-software buildout rather than a pure algorithm vendor model [Business Wire, November 2026] [The Next Web, November 2026] [Ashbyhq, November 2026].

Over the next 12 to 18 months, the public milestones that matter most are evidence of technical validation beyond company framing, clearer definition of buyer and clinical workflow, and any disclosed progress on deployments, partnerships, or regulatory path. For now, the company is easy to take seriously on ambition and financing, while the investability debate still turns on whether Mosaic can convert a compelling surgical-intelligence concept into reproducible clinical performance and adoption signals [Business Wire, November 2026] [Runtime Wire, November 2026].

Thinly sourced -- Core financing details are corroborated by multiple public sources, but several material product and team claims remain company-originated or lightly independently verified.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Seed, total disclosed ~$47,000,000

Company Overview

PUBLIC

Mosaic Intelligence Labs entered the public record in November 2026, when the company announced its emergence from stealth and disclosed $47 million in seed funding [Crunchbase] [Business Wire, November 2026]. The public materials describe a San Francisco-based company developing sensing-enabled instruments, spatial intelligence, and robotic systems for minimally invasive surgery, with an initial emphasis on vascular procedures [Business Wire, November 2026].

The company’s public footprint remains thin, which is typical at this stage. Crunchbase identifies the business as Mosaic Intelligence and places it in San Francisco [Crunchbase], while the company’s own announcement names Dr. Ileana Pirozzi and Dr. Alison “Ali” Kight Mackanic as co-founders and says they met during doctoral studies at Stanford [Business Wire, November 2026]. No founding year or legal-entity filing detail was confirmed in the cited sources used for this section, so the clearest milestone sequence is simply stealth development followed by the November 2026 launch and financing disclosure [Crunchbase] [Business Wire, November 2026].

One source, partially checked -- This section relies on Crunchbase and a company announcement; headquarters and funding are corroborated, but founding details remain primarily company-sourced.

The Product and the Stack

MIXED

Mosaic is describing a surgical platform rather than a single device, and the public record is still narrow enough that the distinction matters. In its stealth exit announcement, the company said it is building "intelligent surgical machines" that combine sensing, spatial intelligence, and robotics to help physicians understand anatomy and instrument position during minimally invasive procedures [Business Wire, November 2026]. Follow-on coverage is directionally consistent, with The Next Web reporting an initial focus on vascular procedures and AI-guided instruments and catheters intended to navigate blood vessels [The Next Web, November 2026], while Runtime Wire described a sensing-enabled catheter and robotic-control system meant to reduce reliance on X-ray guidance and operator feel [Runtime Wire, November 2026].

That claimed architecture lines up with the underlying technical problem in endovascular surgery. These procedures route catheters through blood vessels via small incisions [Cleveland Clinic], and published research indicates that real-time tracking of guidewires and catheters is central to closed-loop robotic control and operator situational awareness [arXiv, 2025]. Research also points to the limits of traditional sensor-embedded tracking approaches, including fabrication complexity and miniaturization constraints [arXiv, 2025]. Mosaic's public materials do not establish clinical performance, regulatory status, or commercial deployment, but they do present a coherent technical thesis: combine sensing hardware, 3D vessel reconstruction, and robotic controls to improve navigation inside anatomy [Runtime Wire, November 2026].

The stack details are only partly visible, and that is where caution is warranted. Mosaic has been reported as working with NVIDIA simulation software, with CEO Ileana Pirozzi saying models trained on synthetic simulation data outperformed models trained only on real medical data [Binance, November 2026]. Hiring adds a modest signal that the company is building both hardware and software in-house, including searches for a Hardware Lead, Software Lead, and Founding Clinically Deployed Engineer in San Francisco [Ashbyhq, November 2026]. Beyond that, any deeper read on tooling or deployment architecture would be speculative, though a combined sensing, controls, and clinical-operations stack is a reasonable interpretation (inferred from job postings) [Ashbyhq, November 2026].

Thinly sourced -- Core product claims rely heavily on company announcement coverage, with partial corroboration from The Next Web, Runtime Wire, Binance, Ashbyhq, Cleveland Clinic, and arXiv.

The Market They Are Entering

Publicly reported

This market matters now because endovascular care is already technically demanding, and the evidence base around robotic navigation, real-time instrument tracking, and radiation reduction is moving from academic possibility toward commercial relevance [Frontiers, 2026] [arXiv, 2025] [Cleveland Clinic].

Mosaic is not entering a neatly bounded software category with a clean third-party TAM, and the available public sources do not supply a named market-sizing report for its exact wedge. The closer public frame is endovascular intervention and robotic-assisted vascular navigation: endovascular surgery is a minimally invasive approach in which clinicians thread catheters through blood vessels to restore flow or remove clots [Cleveland Clinic]. Published technical literature also shows why this wedge attracts venture capital. Real-time tracking of guidewires and catheters is described as essential for closed-loop robotic control, collision avoidance, and operator situational awareness, which places Mosaic in a clinically consequential part of the workflow rather than in a peripheral planning tool category [arXiv, 2025].

Demand drivers in the public record are mostly procedural and ergonomic rather than administrative. Runtime Wire describes Mosaic's product direction as a sensing-enabled catheter and robotic-control system intended to reduce reliance on X-ray guidance and operator "feel" during vascular navigation [Runtime Wire, November 2026]. That aligns with the broader robotics literature, which reports that robotic endovascular systems have already been applied to remote catheter manipulation, guidewire navigation, and device delivery in complex vascular interventions [Frontiers, 2026]. If that clinical need holds in practice, the commercial pull should come from physician precision, workflow standardization, and potentially lower fluoroscopy dependence, though the last point remains an inference from the product framing rather than a demonstrated Mosaic outcome [Runtime Wire, November 2026] [Frontiers, 2026].

The adjacent markets are easier to name than to size from the present record. Mosaic sits at the overlap of surgical robotics, catheter-based vascular intervention, intraoperative sensing, and image-guided navigation software, according to company and press descriptions of sensing instruments, 3D vessel reconstruction, and robotic controls for endovascular surgery [Business Wire, November 2026] [Runtime Wire, November 2026]. Substitute approaches include conventional fluoroscopy-led catheter navigation and sensor-embedded tracking architectures; the technical literature notes that some embedded sensing methods, including Fiber Bragg Grating arrays, can add fabrication complexity, create sensor degradation failure modes, and constrain miniaturization [arXiv, 2025]. That does not validate Mosaic's design, but it does clarify the problem set the company is aiming at.

Regulatory and macro forces are favorable in principle, but still long-cycle. Anything sold into vascular intervention that combines hardware, software, and robotic control is likely to face a higher evidence burden, longer development timelines, and more complex hospital adoption than a software-only clinical tool, even though the public sources do not specify Mosaic's regulatory pathway. At the same time, investor appetite for platform medical devices that can encode scarce procedural expertise appears intact, as shown by Mosaic's $47 million seed financing and the emphasis in coverage on translating expert judgment into repeatable machine guidance [Business Wire, November 2026] [The Next Web, November 2026] [Citybiz, November 2026]. The near-term market question is less whether vascular navigation is important, and more whether a new system can prove enough clinical and workflow value to displace incumbent manual practice.

Market frame	What the public sources support	Source
Core procedure domain	Minimally invasive vascular procedures performed through the vascular system	[The Next Web, November 2026] [Cleveland Clinic]
Technology adjacency	Robotic endovascular manipulation, guidewire navigation, and device delivery are established research and deployment themes	[Frontiers, 2026]
Technical bottleneck	Real-time catheter and guidewire tracking is essential for closed-loop robotic control and operator awareness	[arXiv, 2025]
Legacy substitute	Conventional navigation relies in part on X-ray guidance and operator feel	[Runtime Wire, November 2026]

The table underscores a narrow but meaningful point: the public evidence supports a real clinical workflow problem and several adjacent markets, but not a quantified standalone market size for Mosaic's exact category. Investors should read this as a category-formation bet inside vascular intervention rather than a straightforward share-grab in a mature software segment.

One source, partially checked -- Section relies on one independent clinical explainer, one peer-reviewed review source, one preprint, and single-source press reporting for Mosaic's specific market framing.

The Competitive Field

MIXED Mosaic is positioning itself against a mix of established endovascular robotics programs, imaging-dependent procedural workflows, and catheter-navigation research efforts, with its pitch centered on better intra-body sensing rather than on robot hardware alone [Business Wire, November 2026] [Runtime Wire, November 2026] [Frontiers, 2026].

The competitive map is easier to read by substitute than by direct startup peer, because the available reporting does not name a clean venture set of like-for-like companies. At the incumbent end, the status quo in endovascular intervention remains physician-guided catheter work supported by X-ray imaging and operator experience, a workflow Mosaic is explicitly trying to reduce dependence on [Runtime Wire, November 2026]. In the adjacent technology layer, academic and technical literature points to robotic endovascular systems that already support remote catheter manipulation, guidewire navigation, and device delivery, which means Mosaic is not inventing the category so much as arguing for a different sensing and control stack within it [Frontiers, 2026].

That distinction matters, because the company appears to be competing on perception and navigation quality rather than on procedure ownership today. The reported product thesis combines sensing-enabled instruments, 3D vessel reconstruction, and robotic controls for endovascular surgery, while external technical work underscores that real-time tracking of guidewires and catheters is central to closed-loop control and collision avoidance [Runtime Wire, November 2026] [arXiv, 2025]. If that framing holds, Mosaic's nearest alternatives are not only surgical robots, but also any workflow that can give clinicians enough positional confidence through fluoroscopy, manual skill, or simpler navigation aids.

Mosaic's clearest edge, based on public evidence, is the combination of capital, technical ambition, and a narrow initial wedge. A $47 million seed round is unusually large for a company just emerging from stealth, and the named investor set includes 8VC, Fundomo, Lingotto Innovation, and Obvious Ventures, which should give the company time to build integrated hardware and software rather than rush into a partial product [Business Wire, November 2026] [The Next Web, November 2026]. The founders are publicly described as Stanford-trained scientists, and the open roles span hardware, software, and a clinically deployed engineering function, which is consistent with a team being assembled around translational systems work rather than a single-algorithm product [Business Wire, November 2026] [The Next Web, November 2026] [Ashbyhq, November 2026].

That edge is still perishable. The public record does not yet establish regulatory clearance, commercial deployments, procedure volumes, or a proprietary installed base, and those are the assets that usually harden an early technical lead into a durable one. Even the reported collaboration signals are thin: Mosaic is said to work with NVIDIA simulation software, and HonorHealth has been identified in coverage, but the available sources do not show whether that health-system relationship is a paid customer, a research collaboration, or an evaluation setting [Binance, November 2026].

The company is most exposed where incumbent workflows are already "good enough" or where better-funded platform players can absorb sensing advances into broader procedural systems. Traditional endovascular practice still benefits from entrenched imaging infrastructure and trained physician behavior, and technical literature suggests that prior sensor-embedded tracking approaches have struggled with fabrication complexity, sensor degradation, and miniaturization constraints [arXiv, 2025]. If Mosaic's architecture depends on solving those constraints in a commercially manufacturable catheter, the hardest competition may come less from a named startup and more from the friction of clinical adoption and device engineering itself.

Within the named field, NVIDIA is not a direct procedural competitor, but it is the clearest example of a company that could become strategically important to the outcome. If Mosaic's simulation-driven model development continues to outperform real-data-only approaches, as reported in coverage, NVIDIA benefits as the infrastructure layer behind that workflow [Binance, November 2026]. If that advantage fails to translate into clinically validated navigation gains, Mosaic would be the more exposed party, because its differentiation appears to rest on the sensing-plus-spatial-intelligence stack rather than on an already-distributed robotics platform [Business Wire, November 2026] [Binance, November 2026].

The most plausible 18-month scenario is therefore not a clean winner-take-all contest, but a sorting phase between infrastructure enablers and procedure-layer builders. Winner if X: NVIDIA, if synthetic training and simulation become a standard part of endovascular robotics development, because it can win across multiple developers rather than one product line [Binance, November 2026]. Loser if Y: Mosaic, if reduced reliance on X-ray guidance and operator feel remains a compelling concept but does not convert into validated, deployable catheter performance inside clinical settings, where incumbents already own the operator relationship and hospital workflow [Runtime Wire, November 2026] [Frontiers, 2026].

Opportunity

PUBLIC

The prize here is unusually large because a company that can make endovascular navigation more precise, less operator-dependent, and less reliant on continuous X-ray imaging could become a core technology layer inside a high-value procedural category, not just a point-device vendor [Business Wire, November 2026] [Runtime Wire, November 2026] [Frontiers, 2026].

The headline opportunity is to become a platform supplier for intelligent endovascular intervention: sensing-enabled instruments, spatial reconstruction software, and robotic controls sold into the same clinical workflow [Business Wire, November 2026] [Runtime Wire, November 2026]. That outcome is still early, but it is not purely aspirational. The company emerged with $47 million in seed financing, which is a meaningful capital base for a hardware-software medical program at this stage, and the public description of the stack is notable for covering three linked control points, sensing, anatomy reconstruction, and robotic actuation, rather than a single accessory product [Business Wire, November 2026] [The Next Web, November 2026]. In endovascular surgery, real-time catheter and guidewire tracking matters for closed-loop control and operator awareness, while conventional embedded-sensor approaches carry miniaturization and reliability tradeoffs, so a team that improves navigation without adding unacceptable device complexity is working on a real bottleneck rather than a cosmetic add-on [arXiv, 2025] [Frontiers, 2026].

The most credible growth paths are not all-or-nothing, and they hinge on specific technical or commercial catalysts becoming visible in public.

Scenario	What happens	Catalyst	Why it's plausible
Intelligent catheter wedge	Mosaic first wins adoption through sensing-enabled catheters and navigation assistance in vascular procedures, before broader robotic control becomes the primary revenue layer	Early clinical collaborations or product validation around vascular navigation, where the company is already focused [The Next Web, November 2026]	The company has publicly positioned its initial focus around vascular procedures and AI-guided catheter navigation, which narrows the first beachhead to a workflow where navigation precision is central [The Next Web, November 2026] [Runtime Wire, November 2026]
Spatial intelligence control plane	Mosaic becomes the software-and-controls layer used across multiple minimally invasive tools, with 3D vessel reconstruction and instrument-position awareness as the strategic center	Proof that its sensing and reconstruction stack improves operator situational awareness or reduces dependence on fluoroscopy-heavy workflows [Business Wire, November 2026] [Runtime Wire, November 2026]	Public materials consistently describe the company as building sensing instruments, spatial intelligence, and robotic systems together, which supports a platform reading rather than a single-product reading [Business Wire, November 2026] [Runtime Wire, November 2026]
Synthetic-data advantage in surgical AI	Mosaic builds a defensible training and simulation loop that improves navigation models faster than peers relying mainly on limited real-world procedural data	Continued integration with simulation tooling and evidence that synthetic training data improves model performance in this domain [Binance, November 2026]	Pirozzi said models trained on synthetic simulation data outperformed models trained only on real medical data, and the company is reported to work with NVIDIA simulation software, which points to a potential data and iteration advantage if validated further [Binance, November 2026]

What compounding looks like is straightforward in concept, even if the evidence remains early. Better sensing can improve 3D vessel reconstruction and instrument localization; better localization can improve robotic control and procedural confidence; each deployment can in turn generate more edge cases for simulation and model refinement [Runtime Wire, November 2026] [Binance, November 2026] [arXiv, 2025]. If that loop works, the product gets better as it sees more anatomical variation and more navigation contexts, while hospitals and physicians face switching costs once training, workflow, and capital equipment begin to center on a single navigation stack [Frontiers, 2026]. The current public signals are limited, but the hiring mix, Hardware Lead, Software Lead, and a Founding Clinically Deployed Engineer, is consistent with a company preparing to connect lab development with real clinical environments rather than remaining a research project [Ashbyhq, November 2026].

The size of the win is harder to quantify from the present record because no public market-size figure or directly comparable public peer was provided in the source set. Even so, the upper-bound strategic outcome is clear enough to frame: if Mosaic becomes a differentiated platform in robotic endovascular intervention, combining device revenue, software, and procedure-linked clinical adoption, the company could support venture-scale value creation measured in the multibillion-dollar range (scenario, not a forecast). That framing rests less on disclosed Mosaic metrics, which are absent today, and more on the economic reality that vascular interventions are complex, high-stakes procedures where improvements in navigation, radiation exposure, and operator consistency can matter clinically and financially [my.clevelandclinic.org] [Frontiers, 2026]. The public evidence does not yet justify a narrower valuation range, but it does support the core upside case: Mosaic is aiming at a technically difficult problem inside a consequential procedural market, with enough early capital and architectural ambition to matter if execution holds [Business Wire, November 2026] [The Next Web, November 2026].

Thinly sourced -- This section relies on one independently reported financing event and multiple company-originated product descriptions re-reported by publishers, plus general technical literature on endovascular robotics and catheter tracking [Business Wire, November 2026] [The Next Web, November 2026] [Runtime Wire, November 2026] [Frontiers, 2026] [arXiv, 2025].

Sources

Publicly reported

1. [Business Wire, November 2026] Mosaic Emerges from Stealth with $47 Million to Build Intelligent Surgical Machines - Treating the Body from Inside | https://www.businesswire.com/news/home/20261110289756/en/Mosaic-Emerges-from-Stealth-with-$47-Million-to-Build-Intelligent-Surgical-Machines---Treating-the-Body-from-Inside

2. [The Next Web, November 2026] Mosaic Intelligence Labs raises $47m for AI surgical catheters | https://thenextweb.com/news/mosaic-intelligence-labs-47m-seed-ai-surgical-catheter

3. [Runtime Wire, November 2026] Mosaic Intelligence Labs emerges from stealth with $47M to build sensing surgical robots | https://runtimewire.com/article/mosaic-intelligence-labs-47m-seed-surgical-robots

4. [Ashbyhq, November 2026] jobs.ashbyhq.com/mosaicintelligence | https://jobs.ashbyhq.com/mosaicintelligence

5. [Crunchbase] Mosaic Intelligence - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/mosaic-intelligence-inc

6. [Binance, November 2026] AI Trends: Mosaic raises 47 million in seed funding to develop surgical robotics | https://www.binance.com/en/square/post/11-11-2026-ai-trends-mosaic-raises-47-million-in-seed-funding-to-develop-surgical-robotics-387063225083931

7. [Citybiz, November 2026] Mosaic Emerges From Stealth With $47 Million for Surgical Robotics | https://www.citybiz.co/article/932105/mosaic-emerges-from-stealth-with-47-million-for-surgical-robotics/

8. [LinkedIn] Ileana Pirozzi - Stealth | LinkedIn | https://www.linkedin.com/in/ileanapirozzi/